Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.

Participants will receive placebo capsules by mouth for 28 days.

Healthy Volunteers

Overweight

Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.

Sucralose

Placebo capsule will be taken orally for 28 days

Placebo

National Institutes of Health Clinical Center

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

To determine the effects of sucralose (4 mg/kg/day) administered to overweight and obese minority women for 28 days on drug metabolism using digoxin and midazolam as probes for P-glycoproteinand CYP3A, respectively.

We also aim to determine if consumption of ~4 mg/kg sucralose over a 28-day period leads to:1)changes in glycemia and glucose stimulated secretion of GLP-1 and other gut hormones during an oral glucose tolerance test (OGTT)2)changes in lipid metabolism (in vitro (adipose tissue) and in vivo (fasting and during OGTT) 3)alterations in the intestinal microflora

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

The patient will received a combination of 3 antibiotics :
Rifampicin (10mg/kg once daily)
Ethambutol (15 to 20 mg/kg once daily)
Clarithromycin (500 mg twice daily)

The patient will received a combination of 3 antibiotics :
Rifampicin (10mg/kg once daily)
Ethambutol (15 to 20 mg/kg once daily)
Azithromycin (250 mg once daily)

Lung Infection

Mycobacterium Avium Complex

The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.

Clarithromycin 1000 MG

The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.

Azithromycin 250 mg

The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.

Rifampicin

Ethambutol

CHU Amiens Picardie

Saint Joseph Hospital

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

Three spontaneous sputum specimens will be obtained at baseline and 6 months. If it's not possible to obtain good quality specimens, the clinician may perform three hypertonic aerosol-induced sputum specimens on 3 consecutive days. In the absence of sputum (spontaneous or induced), bronchoscopic aspiration and two post-bronchoscopy sputum specimens will be performed.
Microscopic examination will be performed after auramine or Ziehl-Neelsen stain.
Specimens will be cultured at 37°C after decontamination on Lowenstein-Jensen solid medium and Coletsos medium. Results will be expressed quantitatively as the number of colonies per tube according to a logarithmic scale. Culture on liquid medium will also be performed.
The analysis will be based on the Mycobacteria National Reference Centre microscopy, culture and antibiotic susceptibility test results.

Several criteria will be determined at baseline and at 3 months and then compared to assess clinical improvement :
Presence or absence of cough, sputum, dyspnoea, chest pain and wheezing using a 5-point analogue scale (0=no symptom, 4=permanent symptoms) ;
WHO performance status scored from 0 to 4 ;
Global score from 0 to 24, taking into account the score of the 5 respiratory symptoms and the WHO performance status ;
Presence of blood-stained sputum (haemoptysis greater than 50 mL or requiring specialized medical intervention)
Weight in kg (patient weighed in underwear on the same scales, variations taken into account when greater than 5% of the baseline weight).

Several criteria will be determined at baseline and at 6 months and then compared to assess clinical improvement :
Presence or absence of cough, sputum, dyspnoea, chest pain and wheezing using a 5-point analogue scale (0=no symptom, 4=permanent symptoms) ;
WHO performance status scored from 0 to 4 ;
Global score from 0 to 24, taking into account the score of the 5 respiratory symptoms and the WHO performance status ;
Presence of blood-stained sputum (haemoptysis greater than 50 mL or requiring specialized medical intervention)
Weight in kg (patient weighed in underwear on the same scales, variations taken into account when greater than 5% of the baseline weight).

Several criteria will be determined at baseline and at 12 months and then compared to assess clinical improvement :
Presence or absence of cough, sputum, dyspnoea, chest pain and wheezing using a 5-point analogue scale (0=no symptom, 4=permanent symptoms) ;
WHO performance status scored from 0 to 4 ;
Global score from 0 to 24, taking into account the score of the 5 respiratory symptoms and the WHO performance status ;
Presence of blood-stained sputum (haemoptysis greater than 50 mL or requiring specialized medical intervention)
Weight in kg (patient weighed in underwear on the same scales, variations taken into account when greater than 5% of the baseline weight).

Chest x-ray will be realised at baseline and at 3 months and described according to :
type of lesion: opacity/solitary pulmonary nodule, excavated opacity/ fibrocavitary disease, interstitial syndrome (multiple nodule, dense airspace disease)
precise site (upper lobe, right middle or lower lobe, left lower or upper lobe)

Chest x-ray and chest high-resolution CT will be realised at baseline and at 6 months.
Chest x-ray will be described according to:
type of lesion: opacity/solitary pulmonary nodule, excavated opacity/ fibrocavitary disease, interstitial syndrome (multiple nodule, dense airspace disease)
precise site (upper lobe, right middle or lower lobe, left lower or upper lobe)
Chest CT will be described according to:
type of lesion: nodules, micronodules, bronchiectasis, mass, interstitial syndrome (and its type)
precise site of the segment(s) involved
number of lesions
dimensions of the various lesions (long and short axes) and volume, whenever possible.

Chest x-ray and chest high-resolution CT will be realised at baseline and at 12 months.
Chest x-ray will be described according to:
type of lesion: opacity/solitary pulmonary nodule, excavated opacity/ fibrocavitary disease, interstitial syndrome (multiple nodule, dense airspace disease)
precise site (upper lobe, right middle or lower lobe, left lower or upper lobe)
Chest CT will be described according to:
type of lesion: nodules, micronodules, bronchiectasis, mass, interstitial syndrome (and its type)
precise site of the segment(s) involved
number of lesions
dimensions of the various lesions (long and short axes) and volume, whenever possible.

Microbiological specimens, preferably 3 sputum specimens, will be obtained and processed at 3 months after treatment according to the same modalities as at baseline.

Microbiological specimens, preferably 3 sputum specimens, will be obtained and processed at 12 months after treatment according to the same modalities as at baseline.

The 12-month mortality will be determined by the survival at that date. The date of any death occurring during treatment will be recorded and the interval between the start of treatment and death will be calculated. The cause of death will be investigated and reported.

All adverse events will be notified according to the recommendations. Particular attention will be paid to gastrointestinal adverse effects (the incidence of nausea and vomiting will be recorded). These adverse events will be assessed at each visit according to the Rhodes scale.
Haematological, gastrointestinal and renal toxicities will be scored according to the WHO toxicity scale.

Centre Hospitalier Universitaire, Amiens

Atrial Fibrillation

Congestive Heart Failure

Rate vs rhythm control strategies for atrial fibrillation

rate vs rhythm control strategies in atrial fibrillation

Rate vs rhythm control strategies in atrial fibrillation

Montreal Heart Institute

Atrial Fibrillation and Congestive Heart Failure Trial

Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial

Denis Roy, MD

Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.

End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.

End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.

digoxin/çürük

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

Atrial Fibrillation and Congestive Heart Failure Trial

Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı